NFIC and gastric cancer: In conclusion, it was validated in our study that NFIC-activated LBX2-AS1 accelerated proliferative, migratory and invasive abilities of GC cells by sponging miR-491-5p to up-regulate ZNF703, offering a biomarker for the improvement of GC treatment.